Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates that carvedilol stimulates microRNA maturation through beta-arrestin1 signaling in cardiac cells, indicating a novel pathway for cardioprotection.
Rationale: MicroRNAs (miRs) are small, noncoding RNAs that function to post-transcriptionally regulate gene expression. First transcribed as long primary miR transcripts (pri-miRs), they are enzymatically processed in the nucleus by Drosha into hairpin intermediate miRs (pre-miRs) and further processed in the cytoplasm by Dicer into mature miRs where they regulate cellular processes after activation by a variety of signals such as those stimulated by β-adrenergic receptors (βARs). Initially discovered to desensitize βAR signaling, β-arrestins are now appreciated to transduce multiple effector pathways independent of G-protein–mediated second messenger accumulation, a concept known as biased signaling. We previously showed that the β-arrestin–biased βAR agonist, carvedilol, activates cellular pathways in the heart. Objective: Here, we tested whether carvedilol could activate β-arrestin–mediated miR maturation, thereby providing a novel potential mechanism for its cardioprotective effects. Methods and Results: In human cells and mouse hearts, carvedilol upregulates a subset of mature and pre-miRs, but not their pri-miRs, in β 1 AR-, G-protein–coupled receptor kinase 5/6–, and β-arrestin1–dependent manner. Mechanistically, β-arrestin1 regulates miR processing by forming a nuclear complex with hnRNPA1 and Drosha on pri-miRs. Conclusions: Our findings indicate a novel function for β 1 AR-mediated β-arrestin1 signaling activated by carvedilol in miR biogenesis, which may be linked, in part, to its mechanism for cell survival.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: